PeptideStack
5.2kquestions
20kanswers
220users

How does WWB compare to Shanghai ERP Biotechnology on documentation quality?

Asked 8 Dec 2024Modified 17 months agoViewed 42k times
39

Conditions: WWB · Shanghai ERP Biotechnology.

I have used one of these for a while and I am considering switching, which requires a reason.

What I care about is reproducibility, because a result I cannot repeat is not useful to me.

What does each option buy me, and what does it cost me?

vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
shareeditfollowflag
PO
askedpip_okonjo13k278 Dec 2024
2Have you ordered yet? The pre-order checks and the post-arrival checks are different lists. – m_haraldsen 2 months ago
add a comment

5 Answers

Accepted answer first, then by votes
59

Accepted answer

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

One laboratory, one method, one submission. Otherwise it is not a comparison.

edited 26 Feb 2025 by b_delacroix — corrected a unit error in the worked example

shareimprove this answerflag
BD
answered · acceptedb_delacroix43k3813 Feb 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
63

The honest answer is that most claimed differences between reputable suppliers are inside inter-laboratory noise.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Put another way, lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

Name the laboratory and the dates or the comparison cannot be reproduced.

shareimprove this answerflag
PH
answeredpetra_hovland35k3821 Jan 2025
2This should be linked from the help pages. – p_mkhize 8 months ago
add a comment
43

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

Price per milligram of measured peptide, not per milligram of label claim.

shareimprove this answerflag
SK
answereds_kalniete57k3810 Jan 2025
8I would add a line about writing the accept threshold down first. It is the step everyone skips. – deamidation_watch 9 months ago
Small correction: carriage amortises across the order, which changes small-order economics entirely. – eoin_mcgarry 26 days ago
add a comment
28

Answering this needs the axis. A supplier that is best on paperwork and a supplier that is best on price are both correct answers to different questions.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

The caveat is that a comparison is a snapshot of the lots compared, and lots change.

Use a fixed documentation checklist rather than an impression.

edited 26 Feb 2025 by nkem_obiora — added a caveat about sampling

shareimprove this answerflag
NO
answerednkem_obiora39k381 Feb 2025
20

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

Compare content, not purity. Purity clusters and content does not.

shareimprove this answerflag
IB
answeredilaria_bertone33k387 Mar 2025
6This is the answer I send people who ask me how to start. – loss_on_drying 4 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.